Anika Therapeutics (ANIK) Depreciation & Amortization (CF) (2010 - 2026)

Anika Therapeutics (ANIK) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 17.58% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $5.6 million, a 7.59% decrease from a year earlier, with the FY2025 full-year figure at $5.4 million, down 21.96% from the prior year.
• Depreciation & Amortization (CF) was $1.5 million for Q2 2026 at Anika Therapeutics, up from $1.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q3 2024 and troughed at $1.3 million in Q2 2025.
• A 5-year average of $1.6 million and a median of $1.6 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) retreated 26.01% in 2025 and rose 17.58% in 2026, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.7 million in 2022, then retreated by 5.35% to $1.6 million in 2023, then retreated by 4.18% to $1.6 million in 2024, then decreased by 15.51% to $1.3 million in 2025, then grew by 14.19% to $1.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.5 million (Q2 2026), $1.4 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.